| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Amane Tateno, Ryosuke Arakawa, Masaki Okumura, Hajime Fukuta, Kazuyoshi Honjo, Keiichi Ishihara, Hiroshi Nakamura, Shin-ichiro Kumita, Yoshiro Okub. Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia. Journal of clinical psychopharmacology. vol 33. issue 2. 2013-08-26. PMID:23422369. |
the clinical implications obtained in this study were the optimal therapeutic dose range of 12.9 to 22.1 mg/d of blonanserin required for 70% to 80% dopamine d(2) receptor occupancy in the striatum, and the good blood-brain barrier permeability that suggested a relatively lower risk of hyperprolactinemia. |
2013-08-26 |
2023-08-12 |
human |
| Di Wang, Hei Kiu Wong, Li Zhang, Grainne M McAlonan, Xiao-Min Wang, Stephen Cho Wing Sze, Yi-Bin Feng, Zhang-Jin Zhan. Not only dopamine D2 receptors involved in Peony-Glycyrrhiza Decoction, an herbal preparation against antipsychotic-associated hyperprolactinemia. Progress in neuro-psychopharmacology & biological psychiatry. vol 39. issue 2. 2013-03-19. PMID:22796279. |
not only dopamine d2 receptors involved in peony-glycyrrhiza decoction, an herbal preparation against antipsychotic-associated hyperprolactinemia. |
2013-03-19 |
2023-08-12 |
rat |
| Laura D Ratner, Betina Gonzalez, Petteri Ahtiainen, Noelia P Di Giorgio, Matti Poutanen, Ricardo S Calandra, Ilpo T Huhtaniemi, Susana B Rull. Short-term pharmacological suppression of the hyperprolactinemia of infertile hCG-overproducing female mice persistently restores their fertility. Endocrinology. vol 153. issue 12. 2013-01-31. PMID:23117930. |
in the present study, we analyzed the influence of the hyperprolactinemia of hcgβ+ females on their reproductive phenotype by treating them with the dopamine agonists, bromocriptine and cabergoline. |
2013-01-31 |
2023-08-12 |
mouse |
| Seyyed Morteza Taghavi, Seyyede Sedighe Fatemi, Hale Rokn. Cabergoline effect on blood sugar in type 2 diabetic patients with oral agent failure. The Medical journal of Malaysia. vol 67. issue 4. 2013-01-16. PMID:23082447. |
ergot-derived dopamine d2 receptor agonists are the usual treatment of hyperprolactinemia and parkinson's disease and recently bromocriptine has been approved for the treatment of type 2 diabetes. |
2013-01-16 |
2023-08-12 |
Not clear |
| Eiji Kirin. Efficacy and safety of aripiprazole in child and adolescent patients. European child & adolescent psychiatry. vol 21. issue 7. 2012-11-26. PMID:22447196. |
aripiprazole (apz) has a unique pharmacological profile, as a partial agonist at the dopamine d2 and serotonin 5ht1a receptors and an antagonist at the serotonin 5ht2a receptor; this drug has few side effects (such as extrapyramidal syndrome, hyperprolactinemia, weight gain, metabolic disorders, and sedation) which are typical problems with other antipsychotic drugs. |
2012-11-26 |
2023-08-12 |
Not clear |
| W R Crowley, G V Shah, H Watanobe, C E Grosveno. Effects of Neonatal Exposure to Estradiol on Prolactin Secretion and Activity of the Tubero-lnfundibular Dopamine System in Young Adulthood: Comparison with Neonatal Prolactin Deficiency*. Journal of neuroendocrinology. vol 2. issue 1. 2012-10-02. PMID:19210392. |
abstract previous results from this laboratory indicate that female rats who consume milk deficient in prolactin (prl) during the neonatal period subsequently display hyperprolactinemia, associated with decreased activity in the tubero-infundibular dopamine (da) system and decreased lactotrope responsiveness to da receptor stimulation. |
2012-10-02 |
2023-08-12 |
rat |
| Hedi Orbach, Gisele Zandman-Goddard, Mona Boaz, Nancy Agmon-Levin, Howard Amital, Zoltan Szekanecz, Gabriella Szucs, Josef Rovensky, Emese Kiss, Andrea Doria, Anna Ghirardello, Jesus Gomez-Arbesu, Ljudmila Stojanovich, Francesca Ingegnoli, Pier Luigi Meroni, Blaz' Rozman, Miri Blank, Yehuda Shoenfel. Prolactin and autoimmunity: hyperprolactinemia correlates with serositis and anemia in SLE patients. Clinical reviews in allergy & immunology. vol 42. issue 2. 2012-08-03. PMID:21287295. |
these results suggest that dopamine agonists may be an optional therapy for lupus patients with hyperprolactinemia. |
2012-08-03 |
2023-08-12 |
human |
| Francesco Porta, Alessandro Mussa, Daniela Concolino, Marco Spada, Alberto Ponzon. Dopamine agonists in dihydropteridine reductase deficiency. Molecular genetics and metabolism. vol 105. issue 4. 2012-07-16. PMID:22325981. |
both patients experienced residual symptoms of dopamine deficiency, movement and behavioral disability, and complications of l-dopa therapy, associated with fluctuating hyperprolactinemia. |
2012-07-16 |
2023-08-12 |
Not clear |
| Rosalie Broekhof, Manon J Gosselink, Hanno Pijl, Erik J Gilta. The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis. General hospital psychiatry. vol 34. issue 2. 2012-07-09. PMID:21872335. |
highly potent dopamine d(2) receptor antagonistic antipsychotics may induce hyperprolactinemia. |
2012-07-09 |
2023-08-12 |
Not clear |
| Chih-Chin Lu, Ching-Jung Hsie. The importance of measuring macroprolactin in the differential diagnosis of hyperprolactinemic patients. The Kaohsiung journal of medical sciences. vol 28. issue 2. 2012-06-04. PMID:22313536. |
this study investigated the differences in clinical and laboratory features as well as treatment response in 70 outpatients with macroprolactinemia and monomeric hyperprolactinemia treated with dopamine agonists. |
2012-06-04 |
2023-08-12 |
Not clear |
| Richard J Wix-Ramos, Reinalis Paez, Eduardo Capote, Uribe Ezequie. Pituitary microadenoma treated with antipsychotic drug aripiprazole. Recent patents on endocrine, metabolic & immune drug discovery. vol 5. issue 1. 2012-04-06. PMID:22074578. |
we also consider the correlation of drug use in patient with psychosis, haloperidol treatment, pituitary microadenoma syndrome, hyperprolactinemia, and dopamine d2- receptor partial agonist aripiprazole treatment. |
2012-04-06 |
2023-08-12 |
Not clear |
| Alberto M Pereir. Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia. Current opinion in endocrinology, diabetes, and obesity. vol 18. issue 4. 2012-02-15. PMID:21844709. |
update on the withdrawal of dopamine agonists in patients with hyperprolactinemia. |
2012-02-15 |
2023-08-12 |
Not clear |
| Alberto M Pereir. Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia. Current opinion in endocrinology, diabetes, and obesity. vol 18. issue 4. 2012-02-15. PMID:21844709. |
despite the widespread use of dopamine agonists for patients with prolactinomas and symptomatic idiopathic hyperprolactinemia for many decades, the optimal treatment strategy and duration of treatment is still not evident. |
2012-02-15 |
2023-08-12 |
Not clear |
| Alberto M Pereir. Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia. Current opinion in endocrinology, diabetes, and obesity. vol 18. issue 4. 2012-02-15. PMID:21844709. |
this review highlights the effects of dopamine agonist withdrawal in patients with idiopathic hyperprolactinemia and prolactinomas in detail, including the factors influencing the success of treatment outcome. |
2012-02-15 |
2023-08-12 |
Not clear |
| Luiz Eduardo Armondi Wildemberg, Leonardo Vieira Neto, Giselle Fernandes Taboada, Aline Barbosa Moraes, Jorge Marcondes, Flávia Lúcia Conceição, Leila Chimelli, Mônica Roberto Gadelh. Sellar and suprasellar mixed germ cell tumor mimicking a pituitary adenoma. Pituitary. vol 14. issue 4. 2012-01-26. PMID:19116786. |
hyperprolactinemia was also present and dopamine agonist therapy was started. |
2012-01-26 |
2023-08-12 |
Not clear |
| Guillermina María Luque, Maria Ines Perez-Millán, Ana Maria Ornstein, Carolina Cristina, Damasia Becu-Villalobo. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas. The Journal of pharmacology and experimental therapeutics. vol 337. issue 3. 2011-07-19. PMID:21406548. |
d2r knockout [drd2(-/-)] mice have chronic hyperprolactinemia and pituitary hyperplasia and provide an experimental model for dopamine agonist-resistant prolactinomas. |
2011-07-19 |
2023-08-12 |
mouse |
| Takeshi Kunimatsu, Juki Kimura, Hitoshi Funabashi, Tadashi Inoue, Takaki Sek. The antipsychotics haloperidol and chlorpromazine increase bone metabolism and induce osteopenia in female rats. Regulatory toxicology and pharmacology : RTP. vol 58. issue 3. 2011-06-23. PMID:20709132. |
also, it appears that chronic hyperprolactinemia and maintained corpora lutea leading to bone loss are commonly inducible in female rats receiving long-term treatment with antipsychotic drugs possessing dopamine d2 receptor antagonist activity. |
2011-06-23 |
2023-08-12 |
rat |
| Sheba M J MohanKumar, Badrinarayanan S Kasturi, Andrew C Shin, Priya Balasubramanian, Ebony T Gilbreath, Madhan Subramanian, Puliyur S Mohankuma. Chronic estradiol exposure induces oxidative stress in the hypothalamus to decrease hypothalamic dopamine and cause hyperprolactinemia. American journal of physiology. Regulatory, integrative and comparative physiology. vol 300. issue 3. 2011-05-09. PMID:21178126. |
chronic estradiol exposure induces oxidative stress in the hypothalamus to decrease hypothalamic dopamine and cause hyperprolactinemia. |
2011-05-09 |
2023-08-12 |
rat |
| Raul Gómez, Antonio Abad, Francisco Delgado, Silvia Tamarit, Carlos Simón, Antonio Pellice. Effects of hyperprolactinemia treatment with the dopamine agonist quinagolide on endometriotic lesions in patients with endometriosis-associated hyperprolactinemia. Fertility and sterility. vol 95. issue 3. 2011-04-22. PMID:21055747. |
effects of hyperprolactinemia treatment with the dopamine agonist quinagolide on endometriotic lesions in patients with endometriosis-associated hyperprolactinemia. |
2011-04-22 |
2023-08-12 |
Not clear |
| Jae Won Hong, Mi Kyung Lee, Sun Ho Kim, Eun Jig Le. Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma. Endocrine. vol 37. issue 1. 2011-03-03. PMID:20963563. |
patients were divided into three groups according to treatment outcomes and pathologic results: (a) prolactinoma that responded to dopamine agonist (da) treatment (prda); (b) prolactinoma requiring surgical treatment (prs); and (c) non-functioning pituitary adenoma with hyperprolactinemia (nfpah). |
2011-03-03 |
2023-08-12 |
Not clear |